Caspian is pursuing a potentially disease-modifying approach aimed at restoring the body’s own insulin producing capacity through the selective expansion and improved function of the pancreatic β cells.

Building on Kura Oncology’s pioneering work in menin inhibition, Caspian Therapeutics is advancing a portfolio of menin inhibitors, including KO-7246, as a treatment for diabetes and other chronic metabolic diseases.